Alembic Limited
ALEMBICLTD · NSE · Real Estate
With a 20% margin of safety, our buy-below price is ₹101.65.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%13.3%
- ✓Low debt (D/E < 0.5)0.00x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-0%
- ✕Earnings growing-2%
- ✓Net margin ≥ 10%132.2%
- ✓Current ratio > 1.51.95
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 10.47
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (132.2%).
- •Financially solid — Altman Z 10.47.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Trades ~42% below our estimated fair value.
Threats
- •Earnings contracting year on year.
About Alembic Limited
Alembic Limited engages in real estate business in India and internationally. It operates through Active Pharmaceutical Ingredient (API) and Real Estate segments. The company constructs residential and commercial real estate projects; provides project management and marketing consultancy services; and leases commercial properties
More in Real Estate
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.